Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial by Evans, Rebecca N et al.
Long-term Visual Outcomes after Release
from Protocol in Patients who Participated
in the Inhibition of VEGF in Age-related
Choroidal Neovascularisation (IVAN) Trial
Rebecca N. Evans, MSc,1 Barnaby C. Reeves, DPhil,1 Dawn Phillips, BSc,1 Katherine Alyson Muldrew, PhD,2
Chris Rogers, PhD,1 Simon P. Harding, FRCOphth,3 Usha Chakravarthy, MD, PhD,2 on behalf of the IVAN Study
Group
Purpose: To describe visual outcomes, frequency of treatment and monitoring visits, and antievascular
endothelial growth factor drugs used in usual care in participants who exited a trial in which treatment for neo-
vascular age-related macular degeneration (nAMD) was initiated with bevacizumab or ranibizumab.
Design: Multicenter cohort study up to 7 years after trial exit.
Participants: Patients enrolled in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN)
trial; after excluding participants from 2 sites and who died or withdrew during the trial, 537 were included in this
follow-up cohort.
Methods: Data were collected between May 26, 2016, and August 24, 2017. Distance visual acuity (DVA)
(letters read) in both eyes and treatments for nAMD administered to either eye at all usual care visits were extracted
from medical records of all participants until the point of data collection (duration of study eye monitoring).
Main Outcome Measures: Rate of change of DVA during active surveillance of the study eye (study eye
monitoring), estimated using a multivariable linear random effects model. Other outcome measures were visit and
treatment frequency and switches in antievascular endothelial growth factor (VEGF) drug.
Results: Data were obtained for 99% (532/537) of eligible participants. The median duration of study eye
monitoring after IVAN exit was 3.3 years (interquartile range [IQR], 1.3e4.7), and median DVA was 58.0 letters
(IQR, 34.0e73.0). Study eye DVA deteriorated by 4.3 (95% confidence interval [CI], 3.7e4.9) letters per year.
Injection rate did not influence the rate of change in DVA after adjusting for key covariates. After IVAN exit, 174
participants (32%) received no treatment; 332 of 358 (93%) were treated first with ranibizumab, 78 (23%) of whom
switched to aflibercept. The DVA was similar among participants who switched or did not switch at the end of
study monitoring.
Conclusions: Approximately 5 years after the IVAN study finished, with unprecedented completeness of
follow-up for such a trial, the trajectory of functional decline in the study eye was shown to be greater than that
previously reported for incomplete trial cohorts. Anti-VEGF injection rates and treatment switches were not
important factors in determining visual acuity outcomes. Ophthalmology 2020;127:1191-1200 ª 2020 by the
American Academy of Ophthalmology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.The current standard of care for managing neovascular age-
related macular degeneration (nAMD) is treatment with
biological molecules that bind or suppress antievascular
endothelial growth factor (VEGF) therapies. Commonly
used agents are ranibizumab, bevacizumab, and aflibercept.
The benefits of these agents over 2 years of treatment have
been thoroughly evaluated in well-designed randomized
controlled trials (RCTs).
Outcomes beyond 2 years, on average, at 5 and 7 years
after release from protocol,1-3 have been characterized by
follow-on studies of participants previously enrolled inª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/). Published by Elsevier Inc.RCTs. However, these reports are subject to bias because of
incomplete follow-up, for a variety of reasons: the age of
patients with nAMD, which is approximately 80 years, the
associated high levels of morbidity and mortality, and pa-
tients’ ability to pay.4
Data from real world datasets also show that more than
two-thirds of the patient population are no longer under
review by an ophthalmologist 4 years after starting treat-
ment.5-7 There is broad agreement that visual acuity (VA)
progressively worsens over time. However, because of the
selected nature of the patients for whom data are available,1191https://doi.org/10.1016/j.ophtha.2020.03.020
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estimated in reports of outcomes in subgroups of study
populations who have continued to attend for treatment.5-7
Universal access to care in the United Kingdom’s Na-
tional Health Service provides an opportunity to combine
the advantage of characterizing long-term outcomes in a
phenotypically well-defined trial cohort8 with the advantage
of complete follow-up, minimizing bias. In this report, we
describe the visual outcomes, monitoring and treatment
frequency, cessation of treatment in the study eye, and
survival for up to 5 years in participants who were enrolled
in the IVAN clinical trial.
Methods
The IVAN trial findings and detailed protocol have been
described.8 Briefly, this trial was conducted in 23 sites across the
United Kingdom and enrolled 610 participants with a diagnosis
of treatment naïve nAMD. A factorial design was used with
study eyes randomized to 1 of 2 anti-VEGF drugs ranibizumab
or bevacizumab, and monthly versus treatment as needed.8 After
release from the IVAN protocol (last participant released from
protocol in October 2012), all patients were managed within the
National Health Service with free access to health care. The
IVAN trial,8 including this follow-up study, is covered by the
original trial registration (ISRCTN92166560) and approved by the
office of the research ethics committees Northern Ireland (07/
NIR03/37). Participants’ written informed consent at enrollment in
the IVAN trial allowed for continued follow-up through collection
of clinical data after participants exited the trial but not for any
additional research visit.
For the follow-up study,9 we invited all surviving participants
who had not withdrawn from the trial to confirm their consent
for passive collection of data from their medical records.
Participants were also invited to attend an extra study visit.
Ethics approval was obtained for passive collection of data for
participants who had died during the follow-up period (15/NI/
0177). We also asked surviving IVAN participants if they wanted
to withdraw their original consent, that is, precluding passive data
collection. Those who attended the research visit gave written
informed consent for the extra visit at the time of attendance.
The research adhered to the principles of the Declaration of
Helsinki. An independent study steering committee appointed by
the funder had oversight of the scientific integrity of the follow-up
study.
Study Design
The IVAN follow-up study is a multicenter cohort study of all
participants who had completed the IVAN clinical trial and who
had not withdrawn their consent.
Study Population
The eligible study population for the IVAN follow-up study
comprised 537 of the original 610 participants who completed 24
months of follow-up, had not withdrawn, and had been treated at a
center participating in the follow-up study.
Outcome Measures
The primary outcome was the rate of change in distance visual
acuity (DVA) per year during usual care monitoring and treatment
of the study eye during follow-up (duration of study eye moni-
toring), based on all the routinely collected measurements. These1192measurements were not made to a mandated protocol with
refraction. Thus, we distinguish DVA from best-corrected distance
visual acuities (BCVA), the latter having been obtained during the
IVAN trial or at the research visit for this follow-up study. Other
outcome measures were frequencies of visits and injections during
study eye monitoring, retinal morphology from the most recent
retinal images available (to be reported elsewhere), and length of
survival.
Data Collected
Information extracted from medical records included dates of all
usual care visits, DVA at every visit, and anti-VEGF drug used on
release from protocol and any subsequent changes in treatment
along with the relevant dates. Generic health status using the
EuroQol EQ-5D-5L10 questionnaire, a secondary outcome in the
IVAN trial, was administered at research visits or by post
(nonattenders).
Study Eye Monitoring and Duration of Follow-up
Duration of study eye monitoring after release from protocol was
defined as the period of active surveillance of the study eye only
up to the time of data collection. Study eye monitoring was
considered as having stopped if the patient was described in the
medical record as having been discharged from the participating
hospital clinic into community care or if treatment was only being
administered to the contralateral eye. This latter definition was
applied when the date of the most recent injection to the study eye
was 1 year or more before the most recent usual care visit and
more recent injections were administered only to the fellow eye.
The duration of study eye monitoring was not revised if treatment
was restarted in the study eye after discharge or after study eye
monitoring had been discontinued. All visits and injections were
counted during the period of study eye monitoring. If injections
were recorded with intervals <25 days, these were assumed to be
recording errors and merged with the intervention assigned to
later of the 2 dates.
Statistical Analyses
Demographics were summarized for the entire cohort. Continuous
data are summarized by means and standard deviations (SDs) or
median and IQR if the distribution is skewed. Categoric data are
summarized as numbers and percentages. Time to end of study eye
monitoring or censoring (when information was collected for the
study) and time to other events were summarized in KaplaneMeier
graphs. The DVAs recorded in logarithm of the minimum angle of
resolution or Snellen fraction were mapped to Early Treatment
Diabetic Retinopathy Study (ETDRS) letters as shown in Table S1
(available at www.aaojournal.org). The accuracy of DVA recorded
during usual care was compared with BCVA when the latter were
acquired within 60 days of the date of the DVA measurement.11
Annual monitoring visits and injection rates in the study eye
were calculated for the duration of study eye monitoring. The
number of injections and monitoring visits were summarized for
the cohort as a whole and by BCVA category at IVAN exit, for
each year after release from protocol. Scatterplots of number of
injections and change in DVA for each year after release from
protocol were generated. Information describing the type of anti-
VEGF drug used at release from protocol, switches in the drug
used during study eye monitoring, time to switch, and DVA at
switch is summarized. For study eyes that did not switch, we
estimated the predicted median DVA at the median time to switch
from the mixed effects model described next.
To estimate the average change in DVA, we fitted a multi-
variable mixed effects regression model using all available
Table 1. Visual Acuity in Study Eyes at IVAN Entry and Exit and
End of Study Eye Monitoring
Distance Visual Acuity (Letters)*
Overall (n[532)
N %
IVAN entry (BCVA)
Median (IQR) 65.0 (52.0e74.0)
17 0/532 0.0%
18e37 51/532 9.6%
38e52 83/532 15.6%
53e67 169/532 31.8%
68e82 202/532 38.0%
83 27/532 5.1%
IVAN exit (BCVA)
Median (IQR)y 72.0 (56.0e80.0)
17 5/530 0.9%
18e37 57/530 10.8%
38e52 49/530 9.2%
53e67 95/530 17.9%
68e82 234/530 44.2%
83 90/530 17.0%
End of study eye monitoring (DVA)
Median (IQR)z 58.0 (34.0e73.0)
17 44/499 8.8%
18e37 95/499 19.0%
38e52 71/499 14.2%
53e67 115/499 23.0%
68e82 150/499 30.1%
83 24/499 4.8%
BCVA ¼ best-corrected visual acuity; DVA ¼ distance visual acuity;
IQR ¼ interquartile range; IVAN ¼ Inhibition of VEGF in Age-related
choroidal Neovascularisation.
*All measurements at IVAN entry and exit were BCVA. Measurements at
end of study eye monitoring were clinic records of distance visual acuity.
yData missing for 2 patients.
zData missing for 33 patients.
Evans et al  Anti-VEGF Treatment in the IVAN CohortDVA measurements between release from protocol and end of
study eye monitoring. We did not include the BCVA mea-
surement made at the research visit. The following covariates
were fitted: age at IVAN exit, sex, index of multiple deprivation
(IMD),12 presence of nAMD in fellow eye at IVAN exit, study
better than fellow eye at IVAN exit (defined as study eye
BCVA 5 letters than fellow eye), injection rate in study
eye, and proportion change in lesion size between IVAN
entry and IVAN exit.
Injection rate in the study eye was treated as a time-dependent
variable. For any given year, the rate of injection for the preceding
year was included in the model, estimating the effect of injection
rate in the preceding year on DVA in the subsequent year. Further
details of the statistical methods are given in the Supplementary
material (available at www.aaojournal.org).
Three sensitivity analyses were carried out: (1) excluding
DVA measurements during the first year of follow-up; (2)
including DVA measurements between the end of study eye
monitoring and last recorded usual care visit; and (3) excluding
study eyes with missing covariates. Justifications for these ana-
lyses are described in the Supplementary material (available at
www.aaojournal.org).
Methods for the analyses by original trial allocations, that is,
ranibizumab versus bevacizumab and monthly versus as needed
treatment, are described in the Supplementary material (available at
www.aaojournal.org). All analyses were performed using Stata
version 15.1 (StataCorp LP, College Station, TX).
Results
Description of Cohort
Data collection from usual care medical records and research visits
occurred between May 26, 2016, and August 24, 2017. The cohort
comprised 537 patients who were alive and who had not withdrawn
at IVAN exit at sites that participated in the IVAN follow-up study.
The flow of participants during follow up is shown in Figure S1
(available at www.aaojournal.org). Five participants withdrew
their consent for passive data collection. We obtained data for all
the remaining 532 participants (99%) who were eligible for
inclusion; 413 were still alive, and 199 attended a research visit.
Demographic characteristics, medical history, and blindness
registrations by original trial allocations are shown in Tables S2
to S4 (available at www.aaojournal.org).
Duration of Study Eye Monitoring
Time to end of study eye monitoring is shown by BCVA category
at IVAN exit in Figure S2 (available at www.aaojournal.org). Only
eyes in the worst VA category (<37 letters) at IVAN exit were
monitored for substantially less time. The status of study eyes at
the end of study eye monitoring was: monitoring continuing
41%; monitoring of fellow eye only 7%; discharged 28%;
deceased 14%; other (e.g., care transferred to a nonparticipating
hospital) 9%. The median duration of study eye monitoring was
3.3 years (interquartile range [IQR], 1.3e4.7 years). The
numbers of clinic visits and intravitreal injections administered
during study eye monitoring are shown in Table S5 (available at
www.aaojournal.org).
Distance Visual Acuity at End of Study
Monitoring
In the entire cohort, the median BCVA at the IVAN exit visit was
72.0 letters (IQR, 56.0e80.0), and median DVA at the end of study
eye monitoring was 58.0 letters (IQR, 34.0e73.0), indicating a lossof approximately 14 letters (Table 1). The median change from
BCVA at IVAN exit to DVA at end of study eye monitoring
was less 10 letters (IQR, 22.0 to 2.0). At the end of study
eye monitoring, one third (35%) had a VA better than 68 letters.
Approximately one-fifth (20.8%) had a VA of worse than 33 let-
ters (20/200), and half of these (8.8%) had a VA worse than 18
letters, representing severe vision loss. The change in DVA during
study eye monitoring is shown by BCVA category at IVAN exit in
Figure S3 (available at www.aaojournal.org).Validation of DVA versus Best-Corrected Visual
Acuity
Of the usual care DVA measurements, 87% were measured on
ETDRS charts and recorded as letter scores (66%) or in logarithm
of the minimum angle of resolution notation (21%). Snellen frac-
tions constituted 11%, and hand movements, perception of light,
and no perception of light constituted 2%. The BlandeAltman plot
in Figure S4 (available at www.aaojournal.org) of the mean
difference in DVA and BCVA (DVA minus BCVA) among
those who attended the research visit within 60 days of their
most recent monitoring visit (n ¼ 95/199) was 1.8 letters
(95% confidence interval [CI], 4.3 to 0.6), and the average
interval between the measurements was 21 days (standard
deviation, 23.8).1193
Figure 1. Median injection (left) and visit rate (right) per year since Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) exit by best-
corrected visual acuity (BCVA) category at IVAN exit. Patients with no appointments since IVAN exit (n ¼ 26) and patients with no visual acuity (VA)
since IVAN exit (n ¼ 7) are excluded. Patients monitored for less than 28 days during any given year are excluded from that years’ summary. Pairs of
injections that were recorded within 25 days of each other were assumed to be recording errors and merged with the intervention assigned to later of the 2
dates (n ¼ 57 pairs). The best-corrected visual acuity (BCVA) at IVAN exit is missing for n ¼ 2 patients. IQR ¼ interquartile range.
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Study Eye Monitoring
A total of 5695 injections were recorded. Rates of monitoring visits
and injections are shown for each year of follow-up in Figure 1 and
Table S6 (available at www.aaojournal.org). When classified by
BCVA category at the IVAN exit visit, the lowest category (37
letters) had fewer visits compared with visit rates for the other
BCVA groups, which were all similar. Injection rates in the first
4 years of follow-up showed the same pattern, higher for the
best 3 categories of BCVA at IVAN exit and lowest in the worst
BCVA category. In year 5, the injection rate decreased in the
BCVA category of 38 to 53 letters and became similar to that of the
worst category. For the entire cohort, the number of injections
administered to the study eye was unrelated to the change in DVA
in that year (Fig 2).
Switches in Treatment and Change in Distance
Visual Acuity by Switch Status
The first anti-VEGF drug administered after release from protocol
and subsequent switches in therapy are shown in Figure 3. The
majority of study eyes were commenced on ranibizumab at IVAN
exit, and few were on bevacizumab or aflibercept. During study
eye monitoring, the majority of switches were from ranibizumab
to aflibercept (Fig S5, available at www.aaojournal.org).
Approximately one-third (174) of study eyes did not receive any
further treatments during follow-up, and the median DVA in this
group at end of study eye monitoring was 58.0 (IQR, 33.0e73.0)
with a median follow-up of 1.0 year (IQR, 0.1e2.2).
Of the 358 participants who continued to receive treatments on
release from protocol the majority (93%, n ¼ 332) were
commenced on ranibizumab. During follow-up, 78 participants
were switched from ranibizumab to aflibercept and 10 were
switched to bevacizumab. Demographic characteristics and medi-
cal history by study eyes that switched versus those that did not
switch are described in Table S7 (available at
www.aaojournal.org). The median time to switch was 2.7 years,
and the median time from switch to end of follow-up was 2.3
years (Table 2). The median BCVA in the study eye at IVAN exit1194was similar in switchers at 77 letters (IQR, 70.0e83.0) compared
with non-switchers at 73 letters (IQR, 59.5e80.0). At the time of
switch, the median DVA in study eyes that switched treatment was
64 letters (IQR, 54.5e73.0). In study eyes that did not switch, the
predicted median DVA at the median time to switch (2.7 years)
was 61.2 letters. At the end of study eye monitoring, median DVA
was 60 letters (IQR, 44.0e69.0) in study eyes that switched and 58
letters (IQR, 33.0e73.0) in study eyes that did not switch.Change in Distance Visual Acuity per Year and
Effect of Covariates on Change in Distance
Visual Acuity
Univariable and multivariable associations of time, patient-level
characteristics and their interactions with rate of change in DVA
from IVAN exit to the end of study eye monitoring are reported in
Table 3. Main effects of age, BCVA at IVAN exit, and status of
study eye remained significant in the multivariable analysis after
adjusting for covariates. The model estimated the deterioration in
DVA during study eye monitoring to be 4.3 letters per year
(95% CI, 3.7e4.9) for a participant aged 80 years at IVAN exit.
The only significant interaction was between age and time (P ¼
0.001), with DVA deteriorating faster in older participants and
slower in younger participants (Fig 4); thus, the rate of
deterioration was 3.0 letters per year for a 70-year-old and 5.6
letters per year for a 90-year-old.
Other effects were constant from IVAN exit to the end of study
eye monitoring. Relative to the contralateral eye, the average DVA
of study eyes that were classified as “better seeing” at IVAN exit
was estimated to be 3.9 letters better throughout compared with
study eyes classified as “worse seeing” (Table 3). Injection rate in a
preceding year did not influence the rate of change in vision in the
subsequent year. Change in lesion size during the trial also had no
effect on the rate of change in vision. The 3 sensitivity analyses
shown in Tables S8 to S10 (available at www.aaojournal.org)
showed similar results to that of the main model. Comparisons
of DVA, mortality, and EQ-5D-5L found no differences between
groups by original trial allocations (Figure S6 available at
www.aaojournal.org).
Figure 2. Scatterplots of change in distance visual acuity (DVA) in any given year of follow-up by the number of injections in that year. n ¼ number of
patients monitored during each year with at least 1 DVA reading in that year and in the previous year (to calculate change). Pairs of injections that were
recorded within 25 days of each other were assumed to be recording errors and merged with the intervention assigned to later of the 2 dates (n ¼ 57 pairs).
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This report describes the long-term functional outcomes in
participants in the IVAN trial after release from protocol.
Our main findings were as follows:
 DVA in the study eye deteriorated by more than 4
letters per year during the follow-up period. The rate of
deterioration in DVA was faster for older participants
and slower for younger ones.
 Injection rate did not influence the rate of change in
DVA after taking account of covariates at IVAN exit.
 The majority of study eyes were commenced on
ranibizumab and remained on this treatment
throughout follow-up. Approximately one-fifth of
study eyes switched treatment from ranibizumab to
aflibercept.
Our findings confirm those of other long-term follow-up
studies that anti-VEGF therapy has radically altered the
natural history of untreated nAMD; overall, one-third of
study eyes had a DVA of 68 letters or better 3 to 5 years
after exiting the IVAN trial (i.e., 5e7 years after startinganti-VEGF treatment), maintaining a level of vision that
allowed participants to continue driving. To estimate VA
changes over time in patients receiving anti-VEGF therapy,
investigators have attempted to obtain information on par-
ticipants after exit from major clinical trials.1,2 However, the
completeness of data has been a potential source of bias
since the majority of trials and real world studies have
reported data from less than 50% of their original
cohorts.1-7,13
The most complete follow-up data to date are from the
CATT trial, which measured BCVA 5 years after enrollment
in 647 participants (70.7% of 914 invited to attend a
research visit and 57.9% of those who had completed 2
years in the trial).2 Mean BCVA among this group declined
by 11 letters over 3.5 years since trial exit, that is, 3.14
letters per year. Among those who attended for the
research visit, the mean change in BCVA from IVAN exit
to the research visit provides the best comparison; we
found that this was 19.7 letters over 5.3 years (BCVA at
IVAN exit ¼ 71.5 letters [SD, 14.3] and BCVA at
research visit ¼ 51.8 letters [SD, 26.2]), that is, 3.72
letters per year. This estimate contrasts with the average
reduction in DVA during study eye monitoring when the1195
Figure 3. Flowchart of treatment switches after Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) exit. aSeven of 10 patients switch
again to aflibercept (n ¼ 2); to ranibizumab (n ¼ 2); to ranibizumab then aflibercept (n ¼ 3). bA total of 14 of 78 patients switch again to bevacizumab (n ¼
1); to ranibizumab (n ¼ 5); to ranibizumab then aflibercept (n ¼ 8). cFive of 12 patients switch again to aflibercept (n ¼ 1); to aflibercept then ranibizumab
then aflibercept (n ¼ 1); to bevacizumab then aflibercept (n ¼ 1); to bevacizumab then ranibizumab (n ¼ 1); to bevacizumab then ranibizumab then
aflibercept (n ¼ 1). dOne of 3 patient switches again to ranibizumab (n ¼ 1). eOne of 1 patient switches again: to aflibercept (n ¼ 1). FU ¼ follow-up.
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up are included. We observed a reduction in DVA of 4.3
letters per year, based on the data that were available for
99% of the eligible cohort, highlighting the bias that can
arise when only a selected subset of participants are
considered. This type of bias has likely occurred in thoseTable 2. Time to Treatment Switch and Distance Visual A
Characteristic
Did Not Switchk (n[277)
Sw
Treatmen
Median IQR Median
Time (yrs)
IVAN exit to switch 2.7
Switch to end of SE monitoring 2.3
IVAN exit to end
of SE monitoring
3.5 (1.7e4.7) 5.0
DVA
IVAN exit* 73.0 (59.5e80.0) 77.0
Date of switchy,{ 64.0
End of SE monitoringz 58.0 (33.0e73.0) 60.0
DVA ¼ distance visual acuity; IQR ¼ interquartile range; IVAN ¼ Inhibition
*Data missing for 1 patient (1 did not switch, 0 switched treatments, and 1 no
yData missing for 17 patients (, 17 switched treatments).
zData missing for 33 patients (0 did not switch, 0 switched treatments, 33 no i
kSwitches include ranibizumab to aflibercept (n ¼ 78) and bevacizumab to afli
{Median predicted DVA from mixed effects model (Table 3) at median time t
1196reports in which the estimates of visual acuity decline are
low. For example, Berg et al3 reported an overall loss of 2.1
ETDRS letters compared with baseline after 8 years of
follow-up (and an improvement of 6.1 letters in the first
year) using a treat and extend regimen, but less than 40% of
the original cohort were included in the long-term VAcuity According to Whether Treatment Was Switched
itched
tsk (n[ 81)
No Treatment
Since IVAN Exit (n[174) Overall (n[ 532)
IQR Median IQR Median IQR
(2.0e3.5)
(1.6e2.8)
(4.4e5.7) 1.0 (0.1e2.2) 2.9 (1.1e4.7)
(70.0e83.0) 67.0 (39.0e77.0) 72.0 (56.0e80.0)
(54.5e73.0)
(44.0e69.0) 58.0 (33.0e73.0) 58.0 (34.0e73.0)
of VEGF in Age-related choroidal Neovascularisation; SE ¼ study eye.
injections).
njections).
bercept (n ¼ 3).
o switch (2.7 years) is 61.2 for non-switchers.
Table 3. Effect Estimates from Univariable and Multivariable Models of Distance Visual Acuity in Study Eye during Study Eye Monitoring
Variable
Univariable Multivariable
MD (95% CI) P Value MD (95% CI) P Value P Value for Interaction with Time
Time (per year), multivariable model 4.3 (4.9 to 3.7) - -
Time (per year) 4.3 (4.9 to 3.7) -
Age at IVAN exit (per 10 yrs), centered 3.8 (5.9 to 1.7) - 1.1 (2.1 to 0.1) - -
Age at IVAN exit (per 10 yrs), centered  time 1.2 (2.1 to 0.4) 0.005 1.3 (2.1 to 0.5)z - 0.001
Time (per year) 4.3 (5.1 to 3.5) -
Gender (male) 1.0 (2.2 to 4.2) - 0.5 (1.0 to 1.9) 0.529 0.916
Gender (male)  time 0.4 (0.9 to 1.7) 0.579
Time (per year) 2.8 (4.1 to 1.5) -
Index of multiple deprivation decile 0.4 (0.2 to 0.9) - 0.2 (0.4 to 0.1) 0.193 0.100x
Index of multiple deprivation decile  time 0.2 (0.4 to 0.0) 0.017
Time (per year) 4.2 (4.9 to 3.4) -
BCVA at IVAN exit 68 Ref. - Ref. <0.001 0.398
53e67 18.2 (20.2 to 16.2) 17.0 (19.0 to 15.1)
38e52 31.3 (33.9 to 28.7) 29.5 (32.0 to 27.0)
37 46.5 (48.9 to 44.0) 44.6 (47.0 to 42.1)
BCVA at IVAN exit  time 68 Ref. 0.326
5367 0.9 (2.7 to 0.8)
3852 1.4 (0.8 to 3.6)
37 0.4 (1.9 to 2.8)
Time (per year) 4.5 (5.4 to 3.6) -
nAMD present in fellow eye 3.4 (0.2 to 6.5) - 0.9 (2.6 to 0.7) 0.281 0.202
nAMD present in fellow eye  time 0.6 (0.6 to 1.9) 0.324
Time (per year) 4.4 (5.2 to 3.6) -
Study eye BCVA better than fellow eye at IVAN exit* 12.6 (9.5 to 15.7) - 3.9 (2.0 to 5.7) <0.001 0.172
Study eye BCVA better than fellow eye at IVAN exit  time 0.6 (0.7 to 1.9) 0.371
Time (per year) 4.2 (4.8 to 3.6) -
Injection rate in study eye in previous year (per 3 injections) 0.1 (0.8 to 0.7) - 0.2 (0.9 to 0.5) 0.549 0.056k
Injection rate in study eye in previous year (per 3 injections)  time 0.2 (0.0 to 0.3) 0.056
Time (per year) 4.6 (5.3 to 3.8) -
Proportion change in lesion sizey 0.1 (0.4 to 0.5) - 0.0 (0.1 to 0.1) 0.757 0.178
Proportion change in lesion size  time 0.1 (0.1 to 0.4) 0.159
BCVA ¼ best-corrected visual acuity; CI ¼ confidence interval; DVA ¼ distance visual acuity; IMD ¼ index of multiple deprivation; IVAN ¼ Inhibition of VEGF in Age-related choroidal Neo-
vascularisation; MD ¼ mean difference; nAMD ¼ neovascular age-related macular degeneration.
Injection rate in study eye in previous year (per 3 injections)  time ¼ 0.2 (0.0e0.3)
*Study eye is defined as better than the fellow eye if study eye BCVA 5 letters greater than fellow eye BCVA at IVAN exit.
yProportion change in lesion size between IVAN entry and IVAN exit (lesion size at IVAN exit/lesion size at IVAN entry).
zThis interaction means that in an 80-year-old, the average rate of change in DVA in the study eye was 4.3 (95% CI, 4.9 to 3.7) letters per year but, for every 10-year increase in age, a further 1.3 letters
per year were lost; thus, for a 90-year-old, the rate of change in DVA was 4.3 to 1.3 ¼ 5.6 letters per year. See also Figure 4.
xInteraction not included in final multivariable model. Effect estimates for IMD (main effect) and IMD by time interaction if included in the multivariable model are index of multiple deprivation
decile ¼ 0.1 (0.4 to 0.1). Index of multiple deprivation decile  time ¼ 0.2 (0.4 to 0.1). Model fitted to n ¼ 532 patients. Missing data imputed using multiple imputation methods. Table S10 gives
complete case analysis. Age is centered at the average age (80 years). Because of small effect sizes for each 1-year increase in age, age is scaled per 10 years. Because of the small effect size for each increase in 1
injection, injection rate is scaled, and effect sizes reported are per 3 injections. Univariable models were fitted with time, covariate and time  covariate interaction only. Multivariable models were fitted
with time, all covariates and time  age interaction.
kInteraction not included in final multivariable model. Effect estimates for injection rate (main effect) and injection rate by time interaction if included in the final multivariable model are injection rate in
study eye in previous year (per 3 injections) ¼ 0.5 (1.2 to 0.3).
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Figure 4. Change in distance visual acuity (DVA) by category of age at Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) exit,
DVA calculated from fitted values from the multivariable model.
Ophthalmology Volume 127, Number 9, September 2020outcomes. A recent study of 67 patients reported a mean VA
after 7 years of follow-up of 65 letters (w7 letters better
than baseline) but only included 6.7% of patients who met
their specific follow-up criteria.14
We chose to estimate the change in DVA during study
eye monitoring (i.e., active surveillance), recognizing that
participants might continue to attend usual care visits for
surveillance and treatment of the fellow eye. We considered
this to be the most appropriate period over which to estimate
change, because it represents the time during which there
was active management of the study eye to control neo-
vascular lesion activity. Because we had limited information
on reasons why study eye monitoring was stopped, we
assumed that it ended on the date of the most recent study
eye injection if that date was 1 year or more before the most
recent usual care visit and injections were continuing to the
fellow eye.
The multivariable analysis of DVA showed that the rate
of deterioration during study eye monitoring was unaffected
by the BCVA level at IVAN exit. This finding is concordant
with previously published data on the outcomes of nAMD
treated with anti VEGF therapies.4-7 The multivariable
analysis also revealed a strong interaction between age and
time: DVA declined faster in older participants. Several
studies13,15 have identified increasing age as an adverse
predictor of visual outcome but have merely reported
findings for dichotomized age groups, for example,
comparing those aged 80 years and above with those
younger than 80 years of age. Our finding is of high
clinical relevance both for counseling and in the1198management of patients, acknowledging that age is likely
a proxy for complex underlying comorbidity.
We also provide information on visit and injection rates
by BCVA category at IVAN exit. We observed the lowest
injection rates in study eyes were in the worst BCVA
category at IVAN exit but accompanied by only a margin-
ally lower visit rate compared with the other categories of
BCVA, indicating that monitoring of the study eye was
continuing despite the low level of vision. It was also
notable that study eyes with BCVA better than 38 letters but
less than 67 letters (the 2 middle categories of BCVA at
IVAN exit) had similar visits and injection rates as the best
BCVA category. Of note, injection rate did not significantly
influence the rate of VA loss as shown in the multivariable
model. This finding should be viewed with caution because
it is contrary to other studies that report better VA outcomes
with higher injection rates.13,14,16 In support of our
observation, we have provided information on the
distribution in injection rates across individuals (Figs 1
and 2 and Table S6 [available at www.aaojournal.org] in
addition to the multivariable effects shown in detail in
Table 3). There are 2 reasons why we believe our findings
are robust. First, we calculated injection rate by each year
of follow-up and analyzed its effect as a time-varying co-
variate, along with a sensitivity analysis. Second, we
distinguished between a main effect of injection rate and the
interaction of injection rate and time. Neither effect was
statistically significant, and the point estimates were small
(Table 3): 0.5 letters (main effect, at IVAN exit: eyes read
0.5 letters fewer per additional 3 injections) and 0.2 letters
Evans et al  Anti-VEGF Treatment in the IVAN Cohort(interaction: eyes read 0.2 letters more per year per
additional 3 injections).
We identified a group of study eyes in which the
anti-VEGF agent that was commenced at IVAN exit was
subsequently changed at some point during study eye
monitoring. Compared with study eyes that were maintained
on the same treatment throughout monitoring, switchers
were younger, had marginally better BCVA at IVAN exit,
were monitored for longer, and had similar DVA at the end
of study eye monitoring to non-switchers. We did not
attempt to compare the rate of change in DVA per year in
study eyes or the number of treatments given in switchers
with non-switchers because switch occurred at different
times during study eye monitoring and the comparison
would have been confounded by differences in the charac-
teristics of the participants.
Although CATT reported a higher frequency of treat-
ments compared with IVAN in their 5-year follow-up,2
their visual acuity outcomes were similar to ours.
Westborg et al16 reported an average of 21 injections
over a 7-year period from treatment initiation, and the
gain in VA seen in initial years was lost with a mean
change of 1 letter from baseline at the final follow-up.
However, these represent findings from less than one-
fifth of the original cohort of 322 patients, because data
from 82% were not included.
The data on injection rates in the IVAN follow-up study
are not easily compared with other published data for 2
main reasons. First, most long-term follow-up studies cite
the injection numbers from treatment initiation that will
reflect the high frequency of treatments in the early years
after diagnosis. Second, in these studies, no data are
available on participants lost to follow-up temporarily or
permanently. Most studies have not reported data on rea-
sons for ceasing treatment. Injection rate is also particularly
susceptible to bias from attrition, because injections that are
administered in those who are lost to follow-up cannot be
counted. Unlike in previous studies, we calculated injection
rates for almost all participants after release from trial
protocol, including patients who had died during study eye
monitoring.
Strengths and Limitations
Key strengths of the study are the high proportion of the trial
cohort for whom we collected information and the resistance
to attrition during follow-up of the rate of change in DVA in
usual care, our chosen visual function measure. We were
able to analyze the rate of change in DVA because we
extracted information on this measure at all usual care visits.
We also showed that in a subset of participants who atten-
ded a research visit, DVA at the most recent monitoring visit
agreed well with BCVA measured at the research visit. In
this regard, our data differ markedly from real world
studies5-7 and the longer-term follow-up outcomes reported
on participants previously enrolled in RCTs of anti-VEGF
therapies for nAMD.1-3 Given these strengths, we believe
that our findings should provide a reference of the decline in
visual acuity that ophthalmologists and health policy makersshould expect to observe when treating nAMD with anti-
VEGF drugs over 5 to 7 years after starting treatment.
There are 4 main limitations of the study. First, approx-
imately one-half of the IVAN cohort were being actively
monitored at the time data were extracted. However, we
obtained data on 95% of IVAN participants from their usual
care visits, and their trajectories were estimated over the
period inwhich they received usual care; therefore,we believe
that the estimates of decline in DVA that we show are likely to
represent a truer picture than that reported previously.
Second, for the majority of the cohort we depended on
DVAs measured in usual care. A large proportion of these
were obtained on ETDRS charts, and by comparing DVA
at the last monitoring visit with BCVA at the research visit
among participants who attended a research visit within 60
days, we were able to show the validity of the DVA
measurements (the average difference was only 1.8 let-
ters). Third, we were unable to be sure when monitoring of
the study eye ceased. This date was known when the
fellow eye never developed nAMD during the IVAN trial
or the follow-up study or when the fellow eye had a
nAMD lesion on IVAN entry that was never treated.
However, we did not know the date when study eye
monitoring ceased if the fellow eye developed a nAMD
lesion during the IVAN trial or follow-up study and
continued to receive treatment after treatment to the study
eye ceased. In these instances, we inferred the date on the
basis of the time of cessation of treatment to the study eye
if treatment continued in the fellow eye. Fourth, although
the patterns of re-treatment that we observed suggest in the
main that a pro re nata approach to patient management
was used by the majority of sites, it is possible that a treat-
and-extend posology was being used in some patients
because this has been adopted widely in the United
Kingdom and elsewhere in recent years.14 However, our
data collection finished in August 2017, and we did not
observe the emergence of any change in the patterns of
re-treatment; therefore, we do not have evidence on how
the treat-and-extend posology might have influenced vi-
sual outcomes. Nonetheless, images that were analyzed
from the most recent patient visit suggested that the ma-
jority of eyes had dormant nAMD lesions as key markers
of lesion activity consisting of intraretinal and subretinal
fluid that were absent in the majority of eyes (data not
reported or shown in this article).
In conclusion, 6 years after enrollment in IVAN, we have
shown that approximately one-third of eyes with nAMD
treated with anti-VEGF therapies can retain a level of vision
that is sufficient for driving, but on average DVA de-
teriorates by approximately 4.3 ETDRS letters per year.
Anti-VEGF injection rate was not an important factor in
determining visual acuity outcome because injection rate per
se did not influence the rate of DVA loss. Notable new
findings include the characterization of the higher rate of
visual acuity decline in older people. These data obtained
during the IVAN follow-up study have important implica-
tions for healthcare providers in terms of planning and
resource allocation and for clinicians in terms of patient
counseling and treatment planning.1199
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